Literatur
-
1
Ferri C P, Prince M, Brayne C. et al .
Global prevalence of dementia: a Delphi consensus study.
Lancet.
2005;
366
2112-2117
-
2 Huber G. Psychiatrie. 6. Auflage (1999). Stuttgart; Schattauer; 1999
-
3
Klafki H W, Staufenbiel M, Kornhuber J. et al .
Therapeutic approaches to Alzheimer's disease.
Brain.
2006;
129
2840-2855
-
4
Mayeux R.
Evaluation and use of diagnostic tests in Alzheimer's disease.
Neurobiol Aging.
1998;
19
139-143
-
5
McKeith I G, Galasko D, Kosaka K. et al .
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
Neurology.
1996;
47
1113-1124
-
6
Luis C A, Barker W W, Gajaraj K. et al .
Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample.
Int J Geriatr Psychiatry.
1999;
14
526-533
-
7
The Lund and Manchester Groups .
Clinical and neuropathological criteria for frontotemporal dementia.
J Neurol Neurosurg Psychiatry.
1994;
57
416-418
-
8
Neary D, Snowden J S, Gustafson L. et al .
Frontotemporal lobardegeneration. A consensus on clinical diagnostic criteria.
Neurology.
1998;
51
1546-1554
-
9
Consensus report of the Working Group on: „Molecular and Biochemical Markers of Alzheimer's Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.
Neurobiol Aging.
1998;
19
109-116
-
10
Blennow K.
Cerebrospinal fluid protein biomarkers for Alzheimer's disease.
NeuroRx.
2004;
1
213-225
-
11
Dubois B, Feldman H H, Jacova C. et al .
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.
Lancet Neurol.
2007;
6
734-746
-
12
Glenner G G, Wong C W.
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.
Biochem Biophys Res Commun.
1984;
120
885-890
-
13
Kang J, Lemaire H G, Unterbeck A. et al .
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.
Nature.
1987;
325
733-736
-
14
Haass C, Selkoe D J.
Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide.
Cell.
1993;
75
1039-1042
-
15
Güntert A, Döbeli H, Bohrmann B.
High sensitivity analysis of amyloid-β peptide composition in amyloid deposits from human and PS2APP mouse brain.
Neuroscience.
2006;
143 (2)
461-475
-
16
Wiltfang J, Esselmann H, Bibl M. et al .
Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1–37 / 38 / 39 in addition to 1–40 / 42 in Alzheimer's disease and in patients with chronic neuroinflammation.
J Neurochem.
2002;
81
481-496
-
17
Bibl M, Mollenhauer B, Esselmann H. et al .
CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
Brain.
2006;
129
1177-1187
-
18
Motter R, Vigo-Pelfrey C, Kholodenko D. et al .
Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
Ann Neurol.
1995;
38
643-648
-
19
Engelborghs S, DeVreese K, Van de Casteele T. et al .
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
Neurobiol Aging.
2007;
in press
-
20
Mollenhauer B, Cepek L, Bibl M. et al .
Tau protein, β-amyloid (1–42) and S100B protein in cerebrospinal fluid of patients with Dementia with Lewy Bodies.
Dement Cogn Geriatr Disord.
2005;
19
164-170
-
21
Riemenschneider M, Wagenpfeil S, Diehl J. et al .
Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration.
Neurology.
2002;
58
1622-1628
-
22
Wiltfang J, Esselmann H, Smirnov A. et al .
β-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.
Ann Neurol.
2003;
54
263-267
-
23
Hulstaert F, Blennow K, Ivanoiu A. et al .
Improved discrimination of AD patients using β-amyloid(1–42) and tau levels in CSF.
Neurology.
1999;
52
1555-1562
-
24
Bibl M, Mollenhauer B, Esselmann H. et al .
CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.
J Neural Transm.
2006;
114
621-628
-
25
Bibl M, Mollenhauer B, Lewczuk P. et al .
Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias.
Mol Psy.
2007;
12
671-680
-
26
Kanai M, Matsubara E, Isoe K. et al .
Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan.
Ann Neurol.
1998;
44
17-26
-
27
Shoji M, Matsubara E, Kanai M. et al .
Combination assay of CSF tau, Aβ1–40 and Aβ1–42(43) as a biochemical marker of Alzheimer's disease.
J Neurol Sci.
1998;
158
134-140
-
28
Shoji M, Matsubara E, Kanai M. et al .
Taps to Alzheimer's Patients: A continuous Japanese Study of Cerebrospinal Fluid Biomarkers.
Ann Neurol.
2000;
48
402
-
29
Shoji M, Kanai M.
Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness.
J Alzheimers Dis.
2001;
25
273-281
-
30
Wiltfang J, Esselmann H, Bibl M. et al .
Amyloid β peptide ratio 42 / 40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load.
J Neurochem.
2007;
101
1053-1059
-
31
Buee L, Bussiere T, Buee-Scherrer V. et al .
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.
Brain Res Brain Res Rev.
2000;
33
95-130
-
32
Billingsley M L, Kincaid R L.
Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.
Biochem J.
1997;
323
577-591
-
33
Jensen M, Basun H, Lannfelt L.
Increased cerebrospinal fluid tau in patients with Alzheimer's disease.
Neurosci Lett.
1995;
186
189-191
-
34
Vigo-Pelfrey C, Seubert P, Barbour R. et al .
Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.
Neurology.
1995;
45
788-793
-
35
Sunderland T, Linker G, Mirza N. et al .
Decreased β-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
JAMA.
2003;
289
2094-2103
-
36
Bibl M, Mollenhauer B, Esselmann H. et al .
Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review.
Dement Geriatr Cogn Disord.
2008;
25
256-265
-
37
Hesse C, Rosengren L, Andreasen N. et al .
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.
Neurosci Lett.
2001;
297
187-190
-
38
Otto M, Wiltfang J, Cepek L. et al .
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease.
Neurology.
2002;
58
192-197
-
39
Itoh N, Arai H, Urakami K. et al .
Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.
Ann Neurol.
2001;
50
150-156
-
40
Vanmechelen E, Vanderstichele H, Davidsson P. et al .
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.
Neurosci Lett.
2000;
285
49-52
-
41
Kohnken R, Buerger K, Zinkowski R. et al .
Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.
Neurosci Lett.
2000;
287
187-190
-
42
Hu Y Y, He S S, Wang X. et al .
Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.
Am J Pathol.
2002;
160
1269-1278
-
43
Hampel H, Buerger K, Zinkowski R. et al .
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Arch Gen Psychiatry.
2004;
61
95-102
-
44 Van Mechelen E, Van Kerschaver E, Blennow K. et al .CSF-Phospho-tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies. In: Iqbal K, Sisodia SS, Winblad B, eds Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. Chichester; John Wiley and Sons Ltd 2001: 285-291
-
45
Maddalena A, Papassotiropoulos A, Mueller-Tillmanns B. et al .
Cerebrospinal Fluid Amyloid β42 / Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia.
Arch Neurol.
2003;
60
1202-1206
-
46
De Jong D, Jansen R WMM, Kremer B PH. et al .
Cerebrospinal Fluid Amyloid β42 / Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia.
J Gerontol A Biol Sci Med Sci.
2006;
61
755-758
-
47
Herukka S K, Hallikainen M, Soininen H. et al .
CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.
Neurology.
2005;
64
1294-1297
-
48
Olsson A, Vanderstichele H, Andreasen N. et al .
Simultaneous measurement of β-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
Clin Chem.
2005;
51
336-345
-
49
Reijn T S, Rikkert M O, van Geel W J. et al .
Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid β(42) and tau proteins.
Clin Chem.
2007;
53
859-865
-
50
Vanderstichele H, De Meyer G, Andreasen N. et al .
Amino-truncated β-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.
Clin Chem.
2005;
51
1650-1660
-
51
Hansson O, Zetterberg H, Buchhave P. et al .
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Lancet Neurol.
2006;
5
228-234
-
52
Lewczuk P, Kornhuber J, Vanderstichele H. et al .
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study.
Neurobiol Aging.
2008;
29
812-818
-
53
Mulder C, Scheltens P, Visser J J. et al .
Genetic and biochemical markers for Alzheimer's disease: recent developments.
Ann Clin Biochem.
2000;
37
593-607
-
54
Strittmatter W J, Weisgraber K H, Huang D Y. et al .
Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease.
Proc Natl Acad Sci U S A.
1993b;
90
8098-8102
-
55
Galasko D, Chang L, Motter R. et al .
High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Arch Neurol.
1998;
55
937-945
-
56
Riemenschneider M, Schmolke M, Lautenschlager N. et al .
Cerebrospinal β-amyloid (1–42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.
Neurosci Lett.
2000;
284
85-88
-
57
Andreasen N, Minthon L, Davidsson P. et al .
Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice.
Arch Neurol.
2001;
58
373-379
-
58
Sjögren M, Minthon L, Davidson P. et al .
CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging.
J Neural Transm.
2000;
107
563-579
-
59
Sjögren M, Rosgren L, Minthon L. et al .
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD.
Neurology.
2000;
54
1960-1964
-
60
Sjögren M, Davidsson P, Tullberg M. et al .
Both total and phosphorylated tau are increased in Alzheimer's disease.
J Neurol Neurosurg Psychiatry.
2001;
70
624-630
-
61
Blennow K, Wallin A, Agren H. et al .
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease.
Mol Chem Neuropathol.
1995;
26
231-245
-
62
Riemenschneider M, Wagenpfeil S, Diehl J. et al .
Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration.
Neurology.
2002;
58
1622-1628
-
63
Kanemaru K, Kameda N, Yamanouchi H.
Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies.
Neurology.
2000;
54
1875-1876
-
64
Gomez-Tortosa E, Gonzalo I, Fanjul S. et al .
Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Arch Neurol.
2003;
60
1218-1222
-
65
Parnetti L, Lanari A, Amici S. et al .
CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.
Neurol Sci.
2001;
22
77-78
-
66
Galasko D, Marder K.
Picking away at frontotemporal dementia.
Neurology.
2002;
58
1585-1586
-
67
Andreasen N, Minthon L, Davidsson P. et al .
Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice.
Arch Neurol.
2001;
58
373-379
-
68
Bibl M, Mollenhauer B, Wolf S. et al .
Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations.
J Neural Transm.
2007;
114
621-628
-
69
Bibl M, Esselmann H, Otto M. et al .
Cerebrospinal fluid (CSF) amyloid β (Aβ) peptide patterns in Alzheimer's disease (AD) patients and non-demented controls depend on sample pre-treatment: Indication of carrier- mediated epitope masking of Aβ peptides.
Electrophoresis.
2004;
25
2912-2918
-
70
Dermaut B, Kumar-Singh S, Engelborghs S. et al .
A novel presenilin 1 mutation associated with Pick's disease but not β-amyloid plaques.
Ann Neurol.
2004;
55
617-626
-
71
Zekanowski C, Golan M P, Krzysko K A. et al .
Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment.
Exp Neurol.
2006;
200
82-88
-
72
Petersen R C, Doody R, Kurz A. et al .
Current concepts in mild cognitive impairment.
Arch Neurol.
2001;
58 (12)
1985-92
-
73 Förstl H. Lehrbuch der Gerontopsychiatrie und -psychotherapie 2. aktualis. u. erw. Aufl. Thieme Verlag 2003
-
74
Hoglund K, Hansson O, Buchhave P. et al .
Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides.
Neurodegener Dis.
2008, in press;
-
75
Lewczuk P, Kornhuber J, Vanderstichele H.
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study.
Neurobiol Aging.
2008;
29 (6)
812-818
-
76
Blennow K, Wallin A, Hager O.
Low frequency of post-lumbar puncture headache in demented patients.
Acta Neurol Scand.
1993;
88
221-223
-
77
Andreasen N, Minthon L, Davidsson P. et al .
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice.
Arch Neurol.
2001;
58
373-379
-
78
van Oijen M, Hofman A, Soares H D. et al .
Plasma Aβ(1–40) and Aβ(1–42) and the risk of dementia: a prospective case-cohort study.
Lancet Neurol.
2006;
5
655-660
-
79
Ray S, Britschgi M, Herbert C. et al .
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.
Nat Med.
2007;
13
1359-1362
-
80
Bibl M, Esselmann H, Mollenhauer B. et al .
Blood-based neurochemical diagnosis of vascular dementia: a pilot study.
J Neurochem.
2007;
103
467-474
Dr. Mirko Bibl
Klinik für Psychiatrie und Psychotherapie, Universität Duisburg-Essen, Rheinische Kliniken Essen
Virchowstraße 174
45147 Essen
Email: mirko.bibl@lvr.de
Prof. Dr. Jens Wiltfang
Klinik für Psychiatrie und Psychotherapie
Universität Duisburg-Essen
Rheinische Kliniken Essen
Virchowstr. 174
45147 Essen
Email: jens.wiltfang@lvr.de
